The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
 
Benjamin Garmezy
Research Funding - AstraZeneca (Inst); AVEO (Inst); Exelixis (Inst); Jubilant Therapeutics (Inst); Kinnate Biopharma (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); Xencor (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen (Inst); AVEO (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Sanofi (Inst)
 
Cesar Augusto Perez
Research Funding - Accutar Biotech (Inst); Alkermes (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elpiscience (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst)
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Cheng Seok Quah
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Arcus Biosciences; AstraZeneca; Roche/Genentech
Travel, Accommodations, Expenses - Acerta Pharma/AstraZeneca; Arcus Biosciences
 
Betty Tam
Employment - Biomerieux (I); Bristol-Myers Squibb/Celgene; Kinnate Biopharma
Stock and Other Ownership Interests - Biomerieux (I); Kinnate Biopharma
 
Paul Severson
Employment - Kinnate Biopharma; Plexxikon
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan; Kinnate Biopharma
Travel, Accommodations, Expenses - Kinnate Biopharma; Plexxikon